Demirturk, NeseAygen, BilgehanCelik, IlhamiMistik, ResitAkhan, SilaBarut, SenerUral, OnurBatirel, AyseSimsek, FundaErsoz, GuldenInan, DilaraKinikli, SamiTurker, NesrinBilgin, HuseyinGurbuz, YunusTülek, NeclaTarakci, HuseyinYildiz, OrhanTurkoglu, EmineGuzel, Deniz KamalakŞimşek, SümeyraTuna, NazanDemir, Nazlim AktugCagatay, AtahanCetinkaya, Riza AytacKarakecili, FarukHakyemez, Ismail NecatiErtem, Gunay TuncerOrmen, BaharKorkmaz, PinarSili, UluhanKuruuzum, ZiyaSener, AlperOzel, Selcan ArslanOzturk, SinanSuer, KayaCelen, Mustafa KemalKonya, PetekAsan, AliSaltoglu, NeseDogan, Nurhan2024-11-062024-11-062021-02-01https://doi.org/10.5152/tjg.2020.19569https://turkjgastroenterol.org/en/real-world-data-from-turkey-is-sofosbuvir-ledipasvir-with-or-without-ribavirin-treatment-for-chronic-hepatitis-c-really-effective-136736https://hdl.handle.net/11452/47471Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.Methods: Data from patients with chronic hepatitis C treated with SOF/LDV +/- RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed.Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 +/- 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV +/- RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect.Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV +/- RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.eninfo:eu-repo/semantics/openAccessSofosbuvir plus ribavirinGenotype 1 infectionTreatment-naiveAntiviral therapyHcv infectionOpen-labelLedipasvirSafetyLedipasvir/sofosbuvirChronic hepatitis cSofosbuvirLedipasvirSustained virological responseGenotypeReal-world dataGastroenterology & hepatologyArticle00064881640000715516332210.5152/tjg.2020.195692148-5607